Maropitant in veterinary medicine
Review
DOI:
https://doi.org/10.31533/pubvet.v18n03e1567Keywords:
Analgesia, NK-1 antagonist, antiemetic, CereniaAbstract
The objective of this study is to review the literature on the use of maropitant citrate, a specific NK-1 antagonist that inhibits Substance P (SP), which is responsible for sensitizing new nociceptors and the main mediator in the signaling responsible for emesis, therefore originally developed for the treatment of vomiting. However, several studies have shown that Maropitant has great potential as a visceral analgesic after surgery, with the use of the drug individually or in association with another opioid. The research was carried out electronically through platforms such as Google Scholar and Scielo, among others, with the criterion of dogs and cats submitted to ovariohysterectomy (OVH) receiving Maropitant Citrate intravenously (IV) through bolus followed by continuous infusion. It was concluded through the selected studies that the use of maropitant citrate in bolus and continuous infusion, whether or not associated with other drugs, has the potential to promote trans- and postoperative analgesia and anti-inflammatory effects in animals submitted to OVH, reducing the doses of analgesic rescue.
References
Alves, J. E. O., Silveira, M. D., Vieira, E. M. P., & Vidal, L. W. M. (2017). Mecanismos fisiopatológicos da nocicepção e bases da analgesia perioperatória em pequenos animais. Acta Biomedica Brasiliensia, 8(1), 56–68. https://doi.org/10.18571/acbm.122.
Andrade, S. A., & Borges, H. H. G. (2024). Anestesia multimodal com infusão de dexmedetomidina em cadela: Relato de caso. PUBVET, 18(1), e1527. https://doi.org/0.31533/pubvet.v18n01e1527.
Barragán, S. E. S. (2018). Efecto analgésico de citrato de maropitant por goteo continuo en cirugías de ooforo salpingo histerectomía (osh) en caninos. Universidad Técnica de Ambato.
Boscan, P., Monnet, E., Mama, K., Twedt, D. C., Congdon, J., & Steffey, E. P. (2011). Effect of maropitant, a neurokinin 1 receptor antagonist, on anesthetic requirements during noxious visceral stimulation of the ovary in dogs. American Journal of Veterinary Research, 72(12), 1576–1579. https://doi.org/10.2460/ajvr.72.12.1576.
Brainard, B. M., & Hofmeister, E. H. (2012). Anesthesia principles and monitoring. Veterinary Surgery: Small Animal, 2, 248–290.
Cassoli, A. A. S., Palheta Júnior, R. C., & Pereira, R. L. (2021). O maropitant como adjuvante na analgesia visceral em cães e gatos: Revisão. Clínica Veterinária, 150, 50–62.
Chen, O., Donnelly, C. R., & Ji, R.-R. (2020). Regulation of pain by neuro-immune interactions between macrophages and nociceptor sensory neurons. Current Opinion in Neurobiology, 62, 17–25. https://doi.org/10.1016/j.conb.2019.11.006.
Chi, T.-T., & Kraus, B. L. H. (2020). The effect of intravenous maropitant on blood pressure in healthy awake and anesthetized dogs. Plos One, 15(2), e0229736. https://doi.org/10.1371/journal.pone.0229736.
Corrêa, J. M. X., Niella, R. V., Oliveira, J. N. S., Silva Júnior, A. C., Marques, C. S. C., Pinto, T. M., Silva, E. B., Beier, S. L., Silva, F. L., & Lavor, M. S. L. (2021). Antinociceptive and analgesic effect of continuous intravenous infusion of maropitant, lidocaine and ketamine alone or in combination in cats undergoing ovariohysterectomy. Acta Veterinaria Scandinavica, 63(1), 1–8. https://doi.org/10.1186/s13028-021-00615-w.
Corrêa, J. M. X., Soares, P. C. L. R., Niella, R. V, Costa, B. A., Ferreira, M. S., Silva Junior, A. C., Sena, A. S., Sampaio, K. M. O. R., Silva, E. B., & Silva, F. L. (2019). Evaluation of the antinociceptive effect of maropitant, a neurokinin-1 receptor antagonist, in cats undergoing ovariohysterectomy. Veterinary Medicine International, 2019(8), 1–7. https://doi.org/10.1155/2019/9352528.
De la Puente‐Redondo, V., Tingley, F. D., Schneider, R. P., & Hickman, M. A. (2007). The neurokinin‐1 antagonist activity of maropitant, an antiemetic drug for dogs, in a gerbil model. Journal of Veterinary Pharmacology and Therapeutics, 30(4), 281–287. https://doi.org/10.1111/j.1365-2885.2007.00847.x.
Deschamps, K., & Couture, R. (2005). The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation. British Journal of Pharmacology, 145(6), 712–727. https://doi.org/10.1038/sj.bjp.0706249.
Druziaini, J. T., & Druziani, J. T. (2018). Avaliação do potencial analgésico do Maropitant em cadelas submetidas à ovariohisterectomia eletiva.
Favaretto, A. F., Mastrocinque, S., Macedo, J. S., & Rossetti, R. (2022). Maropitant ou cetamina para o controle da dor em cadelas submetidas à ovariohisterectomia. PUBVET, 16(5), 1–8. https://doi.org/10.31533/pubvet.v16n05a1111.1-8.
Fernandes, A. L., Amaral, A. G., Lima, D. A., Lubiana, I. S., Silva, L. G., & Lima, M. P. A. (2021). A utilização do antagonista dos receptores neurocinina-1 (maropitant) na analgesia visceral em pequenos animais. Sinapse Múltipla, 10(1), 13–15.
Friton, G., Thompson, C., Karadzovska, D., King, S., & King, J. N. (2017). Efficacy and safety of injectable robenacoxib for the treatment of pain associated with soft tissue surgery in dogs. Journal of Veterinary Internal Medicine, 31(3), 832–841. https://doi.org/10.1186/s12917-017-1100-x.
Garcia, C., Borges, I. S., Padilha, V. S., Valau, A., & Vargas, D. (2021). Avaliação do efeito analgésico do maropitant em gatas submetidas à ovariohisterectomia eletiva. PUBVET, 15(3), 1–7. https://doi.org/10.31533/pubvet.v15n03a772.1-7.
Garcia-Recio, S., & Gascón, P. (2015). Biological and pharmacological aspects of the NK1-receptor. BioMed Research International, 2015, 1–15. https://doi.org/10.1155/2015/495704.
Gering, A. P., Chung, D. G., Gravena, K., Nazaret, T. L., & Nunes, N. (2015). Anestesia epidural: Revisão de literatura. Revista Científica Eletrônica de Medicina Veterinária, São Paulo, 25, 1–13.
Gomes, L. G., Dower, N. M. B., Stocco, M. B., Martini, A. C., Ferrari, C. C. M., Oliveira, A. C. S., Flôres, F. N., Souza, R. L., & Guimarães, L. D. (2019). Comparison of the effects of maropitant, lidocaine, and dextroketamine administered by the intratesticular route in dogs undergoing elective orchiectomy. Acta Scientiae Veterinariae, 47(1), 1–7. https://doi.org/10.22456/1679-9216.92792.
Grimm, K. A., Lamont, L. A., Tranquilli, W. J., Greene, S. A., & Robertson, S. A. (2015). Veterinary anesthesia and analgesia. John Wiley & Sons.
Grint, N. (2017). Managing acute pain in dogs. In Practice, 39(8), 346–354. https://doi.org/10.1136/inp.j3998.
Jericó, M. M., Andrade Neto, J. P., & Kogika, M. M. (2015). Tratado de medicina interna de cães e gatos. Roca Ltda.
Karna, S. R., Chambers, P., Johnson, C. B., Singh, P., Stewart, L. A., Lopez‐Villalobos, N., & Kongara, K. (2020). Effect of combinations of morphine, dexmedetomidine and maropitant on the electroencephalogram in response to acute electrical stimulation in anaesthetized dogs. Journal of Veterinary Pharmacology and Therapeutics, 43(6), 538–546. https://doi.org/10.1111/jvp.12889.
Kinobe, R. T., & Miyake, Y. (2020). Evaluating the anti-inflammatory and analgesic properties of maropitant: A systematic review and meta-analysis. The Veterinary Journal, 259–260. https://doi.org/10.1016/j.tvjl.2020.105471.
Kraus, B. L. H. (2017). Spotlight on the perioperative use of maropitant citrate. Veterinary Medicine: Research and Reports, 8, 41–51. https://doi.org/10.2147/vmrr.s126469.
Lumb, W. V, Jones, E. W., Téllez, E., & Retana, R. (2017). Anestesia veterinaria. Continental.
Magalhães, E., Govêia, C. S., & Moreira, L. G. (2018). Farmacologia Aplicada à Anestesia. São Paulo: Fontenele Publicações.
Marquez, M., Boscan, P., Weir, H., Vogel, P., & Twedt, D. C. (2015). Comparison of nk-1 receptor antagonist (maropitant) to morphine as a pre-anaesthetic agent for canine ovariohysterectomy. PLoS One, 10(10), e0140734. https://doi.org/10.1371/journal.pone.0140734.
Massone, F. (2017). Anestesiologia veterinária. In Farmacologia e técnicas. Guanabara Koogan.
Muir, W. W., & Hubbell, J. A. E. (2001). Manual de anestesia veterinária. Artmed Editora.
Niyom, S., Boscan, P., Twedt, D. C., Monnet, E., & Eickhoff, J. C. (2013). Effect of maropitant, a neurokinin‐1 receptor antagonist, on the minimum alveolar concentration of sevoflurane during stimulation of the ovarian ligament in cats. Veterinary Anaesthesia and Analgesia, 40(4), 425–431. https://doi.org/10.1111/vaa.12017.
Peixoto, A. J. R., Souza, M. F., Gonring, C., Fernandes, M. E. S. L., Horta, V. G., Coelho, M. C. M., & Silva, M. F. (2023). Fentanil para co-indução de anestesia com propofol em cães pré-medicados com morfina. PUBVET, 17(2), a1348. https://doi.org/10.31533/pubvet.v17n02a1348.
Prada, I. L. S., Massone, F., Cais, A., Costa, P. E. M., & Seneda, M. M. (2002). Bases metodológicas e neurofuncionais da avaliação de ocorrência de dor/sofrimento em animais. Revista de Educação Continuada em Medicina Veterinária e Zootecnia Do CRMV-SP, 5(1), 1–13. https://doi.org/10.36440/recmvz.v5i1.3278.
Schank, J. R., & Heilig, M. (2017). Substance P and the neurokinin-1 receptor: the new CRF. International Review of Neurobiology, 136, 151–175. https://doi.org/10.1016/bs.irn.2017.06.008.
Tranquilli, W. J., Thurmon, J. C., & Grimm, K. A. (2013). Lumb and Jones’ veterinary anesthesia and analgesia. John Wiley & Sons.
Yoshioka, P. S., & Monteiro, J. C. P. (2023). Analgesia visceral com infusão contínua de maropitant em cadelas submetidas a ovariosalpingohisterectomia. PUBVET, 17(13), e1515. https://doi.org/10.31533/pubvet.v17n13e1515.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Rogerio Romeu, Giulia Cappelletto D’Agnoluzzo, Raquel Martina Rodrigues Castillo; Vinicius Lando Borges, Lara Zanetti Patella; Rochelle Gorczak
This work is licensed under a Creative Commons Attribution 4.0 International License.
Você tem o direito de:
Compartilhar — copiar e redistribuir o material em qualquer suporte ou formato
Adaptar — remixar, transformar, e criar a partir do material para qualquer fim, mesmo que comercial.
O licenciante não pode revogar estes direitos desde que você respeite os termos da licença. De acordo com os termos seguintes:
Atribuição
— Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso. Sem restrições adicionais
— Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
